Post-approval studies (Phase 4)Active Not RecruitingNCT05992480What this trial is testingREVIVE (Response to the Ebola Virus Vaccine)Who this might be right forEbola Virus Disease Tulane University 40
Early research (Phase 1)Study completedNCT00605514What this trial is testingEbola and Marburg Virus VaccinesWho this might be right forEbola VaccinesMarburg Virus DiseaseEbola Virus Disease+2 more National Institute of Allergy and Infectious Diseases (NIAID) 20
Early research (Phase 1)Ended earlyNCT03462004What this trial is testingEvaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope GlycoproteinWho this might be right forEbola Virus Disease National Institute of Allergy and Infectious Diseases (NIAID) 15
Large-scale testing (Phase 3)Study completedNCT04556526What this trial is testingA 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant WomenWho this might be right forHealthy Janssen Vaccines & Prevention B.V. 4,031
Early research (Phase 1)Study completedNCT02564575What this trial is testingEvaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy AdultsWho this might be right forHemorrhagic Fever, Ebola National Institute of Allergy and Infectious Diseases (NIAID) 30
Testing effectiveness (Phase 2)Study completedNCT02289027What this trial is testingA Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in SwitzerlandWho this might be right forEbola Vaccines Centre Hospitalier Universitaire Vaudois 120
Testing effectiveness (Phase 2)Study completedNCT05064956What this trial is testingAd26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)Who this might be right forEbola Virus DiseaseEbolaHiv London School of Hygiene and Tropical Medicine 26
Early research (Phase 1)Study completedNCT02314923What this trial is testingPlacebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)Who this might be right forEbola Virus Merck Sharp & Dohme LLC 513
Large-scale testing (Phase 3)Study completedNCT02543268What this trial is testingEvaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult ParticipantsWho this might be right forHealthy Crucell Holland BV 329
Testing effectiveness (Phase 2)Study completedNCT04186000What this trial is testingStudy to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against EbolaWho this might be right forEbola Virus Disease Universiteit Antwerpen 699
Testing effectiveness (Phase 2)Study completedNCT04711356What this trial is testingAd26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)Who this might be right forEbola Virus Disease London School of Hygiene and Tropical Medicine 50
Early research (Phase 1)Study completedNCT02354404What this trial is testingClinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in UgandaWho this might be right forHemorrhagic Fever, Ebola National Institute of Allergy and Infectious Diseases (NIAID) 90
Not applicableStudy completedNCT02911415What this trial is testingOpen Study of the Duration of Immunity After Vaccination With GamEvac-CombiWho this might be right forEbola Hemorrhagic Fever Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 60
Early research (Phase 1)Study completedNCT02464670What this trial is testingOpen-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy VolunteersWho this might be right forEbola Vaccine Inovio Pharmaceuticals 240
Testing effectiveness (Phase 2)Study completedNCT03333538What this trial is testingRandomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-LyoWho this might be right forHealthy Volunteers Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 220
Not applicableUnknownNCT05888649What this trial is testingCommunity Preparedness for Outbreak Response and Readiness for Ebola Vaccination in LiberiaWho this might be right forEbola Virus Disease UL-PIRE Africa Center 1,500
Early research (Phase 1)Study completedNCT00374309What this trial is testingExperimental Vaccine for Prevention of Ebola Virus InfectionWho this might be right forEbola Hemorrhagic FeverEbola Virus DiseaseEbola Virus Vaccines+2 more National Institute of Allergy and Infectious Diseases (NIAID) 48
Not applicableStudy completedNCT02911428What this trial is testingOpen Study of the Duration of Immunity After Vaccination With GamEvacWho this might be right forHemorrhagic Fever, Ebola Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 60
Early research (Phase 1)Study completedNCT04041570What this trial is testingEbola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy AdultsWho this might be right forEbola Virus National Institute of Allergy and Infectious Diseases (NIAID) 40
Testing effectiveness (Phase 2)Study completedNCT02575456What this trial is testingA Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease VaccineWho this might be right forEbola Disease Jiangsu Province Centers for Disease Control and Prevention 500